Global /United States /Healthcare /Biotechnology /IKNA

Ikena Oncology, Inc.

IKNA

• NASDAQ: IKNA • Delayed

1.43USD 4.4%

As of 19 June 2026, Ikena Oncology, Inc. has a market cap of $69.01M USD, ranking #28237 globally and #4247 in the United States. It ranks #2553 in the Healthcare sector, and #494 in the Biotechnology industry.

Global Rank

28237

Country Rank

4247

Sector Rank

2553

Industry Rank

494

Key Stats

Market Cap

$69.01MUSD

Enterprise Value

-$23.37MUSD

EBITDA (TTM)

-$41.22MUSD

Net Income (TTM)

-$30.74MUSD

PB Ratio

0.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Mark Manfredi open_in_new

Employees

Founded

2016

IPO

26 Mar 2021

Website

ikenaoncology.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
4.4%	13%	4.4%	18%	-4.7%	-13%	-14%	-72%	-94%

News

IKNA Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	IKNA Ikena Oncology Inc ISIN: US45175G1085 Shares Out.: Shares Outstanding: 48.258M¹ Shares Float: 20.952M² TV: TradingView: NASDAQ: IKNA SA: Stock Analysis: NASDAQ: IKNA YF: Yahoo Finance: IKNA GF: Google Finance: NASDAQ: IKNA NQ: NASDAQ: IKNA BA: Barron's: IKNA MS: Morningstar: XNAS: IKNA	1.43 USD	TV: TradingView: NASDAQ: IKNA SA: Stock Analysis: NASDAQ: IKNA YF: Yahoo Finance: IKNA GF: Google Finance: NASDAQ: IKNA NQ: NASDAQ: IKNA BA: Barron's: IKNA MS: Morningstar: XNAS: IKNA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Ikena Oncology, Inc.

Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 264K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 232K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 40K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 38K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 36K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 26K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.76B 41.39B EUR 69K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.7B 68.19T KRW 65K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.44B 60.27B AUD 61K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.29B 33.71B CHF 61K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.03B 42.76T KRW 41K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 37K%	-	Germany

chevron_leftBack